Social


Hemophagocytic Lymphohistiocytosis in Still's Disease Dr. Bella Mehta discusses abstract 1143 presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/bFeGK6MTcc https://t.co/cxJg6rQ7gm

New Biomarkers and Therapeutics Show Potential in Still's Disease AOSD is a rare complex, sporadic, systemic autoinflammatory disease similar to sJIA characterized by sustained fever, salmon-colored rash, and arthritis https://t.co/cGBBHsBdK7 https://t.co/a0EwBiTJSu

Systematic review and meta-analysis of efficacy and and safety or therapies in Adult Onset Still's Disease and sJIA IL-1i and IL-6i - highest evidence for treatment Early (<3 months) intervention = higher rate of dz inactivity @RheumNow #ACR23 Abs#2569 https://t.co/XzzwbLFpo7

TM61 at #ACR23 23 yo M p/w ~3mo of sternal swelling - US probable abscess, drained + multiple abx w/ no improvement - XR R shoulder + L elbow nl but MRI abn - MRI L elbow: possible osteomyelitis (OM) - MRI R shoulder; clavicular osteolysis - Bone Bx clavicle + L Ulna: Chronic… https://t.co/7s9PIwByTs https://t.co/wKaKfnncP5


#VEXAS is still hot at #ACR23 - 245K whole genome sequencing data from #NIH All of US - 74 with somatic mutation UBA1 Increased asthma, Tietze’s syndrome and neutropenia Hemoglobin similar in cases and controls @rheumnow #abstL03 https://t.co/A374w60e6H

How do we treat #VEXAS - UBA1 mutation Large multicenter cohort - 110 pts, 99% M Confirms the benefit of JAKi and tocilizumab Others not so much @RheumNow #ACR23 #ACRBest #abstL03 https://t.co/tRjO31IHiD

Defining accuracy of Administrative Codes for Autoinflammatory Syndromes is important to lay groundwork! AOSD, SJIA, BD, FMF, CAPS and SAPHO-CNO ICD codes validated as Autoinflammatory syndromes (AIS)- PPV low @RheumNow #ACR23 #abst1129 https://t.co/XqIrUmUCVc

Nationwide analysis of #AOSD pts with and without #HLH - HLH Much higher in Hispanics Much more in younger pts Abst1143 @rheumnow #ACR23 https://t.co/fluZ4X2HHi

STOP-JIA study data from Abs #0831 suggest improved effectiveness with early combination tx vs step up and biologic first tx at the 2-3 yr timeframe for pJIA pts. More data needed to optimize outcomes/tx for these children. https://t.co/vWL5J4FPbo #ACR23 @rheumnow https://t.co/5iJpwglhPu

Assessment of MAP kinase pathway gene expression prior to tx may aid in identification of polyarticular course JIA patients that could exhibit poor response to tofacitinib. It may be helpful in personalized tx algorithm! #ACR23 Abs #0830 https://t.co/Z8pykbG7x5 @rheumnow https://t.co/ANZr8aVrVB

Efficacy and Safety of Targeted Therapies in #VEXAS Syndrome: Retrospective Study from the French VEXAS Group :) #ACR23 late breaking poster - the figure says it all https://t.co/qahDDPLois https://t.co/ueb4aG8t77

Is there a difference in secukinumab vs. adalimumab biosimilar on radiographic progression in a subgroup of axSpA pts with syndesmophytes or CRP levels? Radiographic progression equally low in both drugs NO difference in syndesmophytes or CRP @RheumNow #ACR23 Abs#0522 https://t.co/1TBKAxuKPE

Good Treatment review of biologics (IL-1, IL-6) in systemic JIA (Stills) including complications of #MAS and lung disease; also info on horizon therapies like JAK inhibitors and IL-18 targeting and novel biomarkers (calgranulins, IL-18 and CXCL9) https://t.co/Cbd7bKdIbb https://t.co/d9tn9fmSAy

Who knew? VEXAS =cluster of findings from a somatic mutation N=110 studying retention of advanced Rx. #JAKi had far better retention than other #Rx. Although there could be channeling bias, I am impressed! Access for off label is a different issue #L03 #ACR23 @RheumNow @ACRheum https://t.co/RE4BVdZeWt

💡RP is a heterogeneous disease. 💡Think VEXAS in RP with MDS. 💡Think MAGIC if oral/genital ulcers. 💡Pts are experts on their own disease! Listen and acknowledge their symptoms. Shout out to Dr @maferradastrong #ACR23 #ImNotYellingImColombian🇨🇴 @ACRheum @RheumNow https://t.co/nTZ96pJh09